Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period

Transfusion

Volumn 43, Issue 7, 2003, Pages 848-852

  Aprili, Giuseppe ^b   Gandini, Giorgio ^b   Piccoli, Pierluigi ^b   Bressan, Fausto ^b   De Gironcoli, Marzia ^b   Mazzi, Romualdo ^b   Parisi, Saverio G ^b   Gessoni, Gianluca ^b   Marchiori, Giorgio ^b   Franchini, Massimo ^a  

^a OSPEDALE POLICLINICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CASE REPORT; COUNSELING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; RNA ANALYSIS; SCREENING TEST; SEROCONVERSION; VIRUS DETECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD DONORS; HIV CORE PROTEIN P24; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RNA, VIRAL;

EID: 0037631729     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00423.x     Document Type: Article

References (29)

1. Schorr JB, Berkowitz A, Cumming PD, et al. Prevalence of HTLV-III antibody in American blood donors. N Engl J Med 1985;313:384-5.
2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334: 1685-90.
3. Ward JW, Holmberg SD, Allen JR, et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med 1988;318:473-8.
4. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
5. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000;284:210-4.
6. Dreier J, Götting C, Wolff C, et al. Recent experience with human immunodeficiency virus transmission by cellular blood products in Germany: antibody screening is not sufficient to prevent transmission. Vox Sang 2002;82:80-3.
7. Velati C, Romanò L, Baruffi L, et al. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002;42:989-93.
8. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
9. Stramer SL. US NAT yield: where are we after 2 years? Transf Med 2002;12:243-53.
10. Grant PR, Busch MP. Nucleic acid amplification technology methods used in blood donor screening. Transf Med 2002;12:229-42.
11. Lelie PN, van Drimmelen HA, Cuypers HT, et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002;42:527-36.
12. Vargo J, Smith K, Knott C, et al. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion 2002;42: 876-85.
13. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002;40:2408-19.
14. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood-bank setting. Lancet 1999;353:359-63.
15. Seifried E, Roth WK. Optimal blood donation screening. Br J Haematol 2000;109:694-8.
16. Petersen L, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;34:283-9.
17. Weber B, Fall EH, Berger A, Doerr HW. Reduction in diagnostic window by new fourth-generation human immunodeficiency virus screening assays. J Clin Microbiol 1998;36:2235-9.
18. Pilcher CD, McPherson IT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002;288:216-21.
19. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002;42:537-48.
20. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002;42:1230-7.
21. Busch MP, Kleinman SH, Jackson B, et al. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious disease. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood donors. Transfusion 2000;40:143-59.
22. Kahn JO, Walker BD. Acute human immunodeficiency virus type I infection. N Engl J Med 1998;339:33-9.
23. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001;134:25-9.
24. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999;319:16-9.
25. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
26. Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy. AIDS 1999;13:1337-42.
27. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8.
28. De Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002;16:1830-2.
29. Roth WK, Weber M, Buhr S. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002;42:862-8.